Ionis Pharmaceuticals Inc
NASDAQ:IONS
Intrinsic Value
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. [ Read More ]
The intrinsic value of one
IONS
stock under the Base Case scenario is
48.38
USD.
Compared to the current market price of 42.2 USD,
Ionis Pharmaceuticals Inc
is
Undervalued by 13%.
IONS's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
IONS or that its price is influenced by factors unrelated to fundamentals.
Ionis Pharmaceuticals Inc's market capitalization is 6.1B USD.
IONS stock price is 42.2 USD.
IONS stock price (42.2 USD) is 13% less than its Intrinsic Value (48.38 USD).
IONS. Open DCF Valuation
IONS stock price (42.2 USD) is 13% less than its Relative Value (48.38 USD). Open Relative Valuation
IONS has upside potential of 34% compared to the average analyst price target.
Open Wall St Estimates
IONS's Revenue has been growing by 3% per year for the last 3 years.
IONS's long-term assets (3B USD) exceed its long-term liabilties (3B USD).
IONS's Revenue is forecast to grow at a rate of 11% per year over the next 3 years.
IONS's Revenue has grown by an exceptional 34% over the past 12 months.
IONS's ROE (Return on Equity) has significantly decreased in the last 3 years from -48% to -76%, and is approaching profitability.
IONS's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -111% to 101%.
IONS has negative Operating Income for the last twelve months.
IONS has negative Net Income for the last twelve months.
IONS's ROE (Return on Equity) for the past 12 months is negative and is equal to -76%.
IONS's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 101%.
IONS has positive Gross Profit for the last twelve months.
IONS has negative Free Cash Flow for the last twelve months.
IONS's D/E (Debt to Equity) is very high and is equal to 3.18.
IONS has negative Net Debt. This means that the company has more cash and short-term investments (4B USD) than debt (1B USD).
IONS has negative three-year average ROE (Return on Equity): -41%. The company is not efficient at transforming stockholders' equity into net income.
IONS has negative three-year average ROIC (Return on Invested Capital): -54%. The company is not efficient at using invested capital to generate operating income.
IONS's short-term assets (3B USD) exceed its short-term liabilties (448m USD).
IONS's Altman Z-Score is very low and is equal to -0.12.
IONS doesn't generate enough operating income (-354m USD) to safely cover interest payments on its debt (7m USD).
Valuation Backtest
Ionis Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
IONS
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Ionis Pharmaceuticals Inc
Balance Sheet Decomposition
Ionis Pharmaceuticals Inc
| Current Assets | 2.6B |
| Cash & Short-Term Investments | 4.3B |
| Receivables | 97.8m |
| Other Current Assets | -1.7B |
| Non-Current Assets | 348.2m |
| PP&E | 242.9m |
| Other Non-Current Assets | 105.3m |
| Current Liabilities | 448.1m |
| Accounts Payable | 26m |
| Accrued Liabilities | 223.7m |
| Other Current Liabilities | 198.3m |
| Non-Current Liabilities | 2.2B |
| Long-Term Debt | 1.2B |
| Other Non-Current Liabilities | 925.8m |
Earnings Waterfall
Ionis Pharmaceuticals Inc
|
Revenue
|
787.6m
USD
|
|
Cost of Revenue
|
-9.1m
USD
|
|
Gross Profit
|
778.5m
USD
|
|
Operating Expenses
|
-1.1B
USD
|
|
Operating Income
|
-353.7m
USD
|
|
Other Expenses
|
-12.6m
USD
|
|
Net Income
|
-366.3m
USD
|
Free Cash Flow Analysis
Ionis Pharmaceuticals Inc
IONS Profitability Score
Profitability Due Diligence
Ionis Pharmaceuticals Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
Score
Ionis Pharmaceuticals Inc's profitability score is 31/100. The higher the profitability score, the more profitable the company is.
IONS Solvency Score
Solvency Due Diligence
Ionis Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Score
Ionis Pharmaceuticals Inc's solvency score is 37/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IONS Price Targets Summary
Ionis Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
IONS
is 56.49 USD
with a low forecast of 29.29 USD and a high forecast of 89.25 USD.
Ownership
IONS Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
IONS Price
Ionis Pharmaceuticals Inc
| Average Annual Return | -12.91% |
| Standard Deviation of Annual Returns | 24.05% |
| Max Drawdown | -66% |
| Market Capitalization | 6.1B USD |
| Shares Outstanding | 145 752 000 |
| Percentage of Shares Shorted | 7.71% |
Company Profile
Ionis Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. The company is headquartered in Carlsbad, California and currently employs 660 full-time employees. The firm is primarily focused on our cardiovascular and neurology franchises. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for the treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. WAYLIVRA is an antisense medicine indicated as an adjunct to diet in adult patients. The firm has over six medicines in Phase III studies for eight indications, which include Eplontersen (TTR), Olezarsen (ApoC-III), Donidalorsen (PKK), ION363 (FUS), Pelacarsen (Apo(a)) and Tofersen (SOD1). Its cardiovascular medicine in development includes Eplontersen, Olezarsen, Pelacarsen, ION449 (PCSK9), Fesomersen and IONIS-AGT-LRx.
Contact
IPO
Employees
Officers
The intrinsic value of one
IONS
stock under the Base Case scenario is
48.38
USD.
Compared to the current market price of 42.2 USD,
Ionis Pharmaceuticals Inc
is
Undervalued by 13%.
You don't have any saved screeners yet
